0.6591
price down icon1.19%   -0.00795
after-market アフターアワーズ: .66 0.00095 +0.14%
loading

Hepion Pharmaceuticals Inc (HEPA) 最新ニュース

pulisher
Oct 26, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN

Oct 26, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 04, 2024

Will Hepion's AMBITION Be Fulfilled? - RTTNews

Oct 04, 2024
pulisher
Sep 23, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Hypha Labs, Inc. Releases Investor Presentation - AccessWire

Sep 23, 2024
pulisher
Sep 23, 2024

Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register

Sep 23, 2024
pulisher
Sep 23, 2024

FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News

Sep 23, 2024
pulisher
Sep 23, 2024

FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

FluoRok Raises £7.7M in Funding - FinSMEs

Sep 23, 2024
pulisher
Sep 23, 2024

Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals

Sep 23, 2024
pulisher
Sep 23, 2024

HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World

Sep 19, 2024
pulisher
Sep 06, 2024

Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com

Sep 06, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK

Sep 04, 2024
pulisher
Sep 04, 2024

Hepion, Pharma Two B file registration statement for proposed merger - TipRanks

Sep 04, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com

Sep 04, 2024
pulisher
Sep 03, 2024

Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.7% Higher - Defense World

Sep 03, 2024
pulisher
Aug 30, 2024

TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga

Aug 30, 2024
pulisher
Aug 21, 2024

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

HEPION PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Aug 19, 2024
pulisher
Aug 13, 2024

GSK, Novartis lead July deals as biopharma sector sees more than $20B for the month - BioWorld Online

Aug 13, 2024
pulisher
Aug 07, 2024

Hepion Pharmaceuticals announces executive leadership changes - Investing.com India

Aug 07, 2024
pulisher
Aug 07, 2024

Hepion Pharmaceuticals announces executive leadership changes By Investing.com - Investing.com UK

Aug 07, 2024
pulisher
Aug 01, 2024

Following restructuring, Hepion to merge with Israeli pharma firm - NJBIZ

Aug 01, 2024
pulisher
Jul 26, 2024

Cingulate (NASDAQ:CING) Stock Quotes, Forecast and News Summary - Benzinga

Jul 26, 2024
pulisher
Jul 24, 2024

HEPA hits 52-week low, trading at 0.7324 USD - Investing.com

Jul 24, 2024
pulisher
Jul 24, 2024

HEPA hits 52-week low, trading at 0.7324 USD By Investing.com - Investing.com Canada

Jul 24, 2024
pulisher
Jul 24, 2024

Oligonucleotide Therapy Market Targeting the Future of Medicine: Oligonucleotide Therapies Offer Precision ... - WhaTech

Jul 24, 2024
pulisher
Jul 23, 2024

Financial Health Check: Examining Hepion Pharmaceuticals Inc (HEPA)’s Key Ratios - The Dwinnex

Jul 23, 2024
pulisher
Jul 23, 2024

Aurora Innovation Inc [AUR] Is Currently -0.71 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Jul 23, 2024
pulisher
Jul 22, 2024

Oligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce Analytic - openPR

Jul 22, 2024
pulisher
Jul 22, 2024

The Globe and Mail - The Globe and Mail

Jul 22, 2024
pulisher
Jul 22, 2024

Oligonucleotide Therapy Market Transforming Healthcare: - openPR

Jul 22, 2024
pulisher
Jul 22, 2024

Hepion Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 1.6118: Will the Stock Break Through? - The InvestChronicle

Jul 22, 2024
pulisher
Jul 22, 2024

The Hepion Pharmaceuticals Inc (HEPA) Stock Is Headed for a Correction - US Post News

Jul 22, 2024
pulisher
Jul 22, 2024

IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings - Markets Insider

Jul 22, 2024
pulisher
Jul 22, 2024

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga

Jul 22, 2024
pulisher
Jul 22, 2024

Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring - TipRanks

Jul 22, 2024
pulisher
Jul 22, 2024

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement - StockTitan

Jul 22, 2024
pulisher
Jul 18, 2024

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga

Jul 18, 2024
pulisher
Jul 13, 2024

Biogen Inc. to Post Q2 2024 Earnings of $4.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:BIIB) - American Banking and Market News

Jul 13, 2024
pulisher
Jul 13, 2024

Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Grows By 58.4% - Defense World

Jul 13, 2024
pulisher
Jul 13, 2024

Glencore (OTCMKTS:GLNCY) Stock Price Passes Above Two Hundred Day Moving Average of $11.24 - American Banking and Market News

Jul 13, 2024
pulisher
Jul 11, 2024

SEC Form S-1 filed by Hepion Pharmaceuticals Inc. - Quantisnow

Jul 11, 2024
pulisher
Jul 03, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 6.5% - Defense World

Jul 03, 2024
pulisher
Jun 28, 2024

Non-alcoholic Steatohepatitis (MASH) Treatment Market - openPR

Jun 28, 2024
pulisher
Jun 04, 2024

Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet ... - Barchart

Jun 04, 2024
pulisher
Jun 04, 2024

Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies - openPR

Jun 04, 2024
pulisher
May 29, 2024

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis - Healio

May 29, 2024
pulisher
May 23, 2024

Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) A Volatile Stock? - Yahoo Canada Shine On

May 23, 2024
pulisher
May 21, 2024

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024 - MSN

May 21, 2024
pulisher
May 11, 2024

Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock? - Yahoo News UK

May 11, 2024
pulisher
May 06, 2024

Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the MarketAbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma - GlobeNewswire

May 06, 2024
pulisher
Apr 24, 2024

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor - PR Newswire

Apr 24, 2024
pulisher
Apr 23, 2024

Hepion shelves Phase II NASH trial amid shallow cash resources - Clinical Trials Arena

Apr 23, 2024
pulisher
Apr 22, 2024

S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings - Benzinga

Apr 22, 2024
pulisher
Apr 19, 2024

Hepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trial - MarketWatch

Apr 19, 2024
pulisher
Apr 02, 2024

Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a shareEarnings Preview - XM

Apr 02, 2024
pulisher
Mar 16, 2024

NASH drug market expected to surpass $48B by 2035 - Seeking Alpha

Mar 16, 2024
pulisher
Mar 06, 2024

Hepion Pharmaceuticals Appoints Michael Purcell to Board - citybiz

Mar 06, 2024
pulisher
Feb 16, 2024

Hepion Pharmaceuticals Bolsters Capital with Equity Deals - TipRanks

Feb 16, 2024
pulisher
Jan 23, 2024

Catherine Warren ousted from Edmonton Unlimited - Taproot Edmonton

Jan 23, 2024
pulisher
Jan 22, 2024

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key CompaniesMediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer - PR Newswire

Jan 22, 2024
$22.32
price down icon 1.11%
$74.12
price up icon 0.26%
$373.97
price up icon 3.48%
$54.36
price down icon 0.66%
$202.64
price down icon 1.63%
$113.10
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):